Tanmiya Capital Fund II

Egypt-focused growth equity fund managed by Cairo-based Tanmiya Capital Ventures (TCV).

African HQ: Egypt

Egypt

2 Portfolio Companies

Investment Range

Not disclosed

Typical check size per portfolio investment

Instruments

Equity

Structure of deployed capital

Technical Assistance

Yes — Provided & Supported

Offers advisory, capacity building, or strategic post-investment support

Target Stages

Growth

Company maturity & growth phase

About the Funder

Egypt-focused growth equity fund managed by Cairo-based Tanmiya Capital Ventures (TCV). Final close of $130M (target $120M) in 2026 with EIB ($37.5M), EAEF, EBRD, IFC and MSMEDA as investors. Backs established, high-growth Egyptian SMEs and mid-caps in healthcare, training, fintech, consumer goods, logistics and transport, expected 6-8 companies.

Investment Thesis & Eligibility

Target Entities

Companies

Mandate & Scope

Combines direct financial capital with technical assistance and governance support.

Regional & Geographic Scope

Active mandate covering Egypt. African headquarters in Egypt.

Portfolio & Backed Ventures (2)

Verified Backed

Copad Pharma

Egyptian pharmaceutical manufacturer producing generic pharmaceutical products, supplements and veterinary products; TCV holds about 21% and an IPO is planned.

EgyptProfile